

*Continuing Education Programme (CEP)*

**Immuno-oncology – safety assessment strategies**

<b>Title</b>	<b>Speaker</b>	<b>Institution</b>
IO therapies – safety assessment strategies for therapeutic antibodies	Dr Lolke de Haan	MedImmune, UK
CD3 engagers and CART cell therapies and the challenges / issues with safety assessment	Jennifer Simms	Integrated Biologix, UK
Utility of disease models in safety assessment of IO therapies – challenges and opportunities	Martyn Foster	Pathology Consultant, UK